Abstract
The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.
Keywords: p53, MDM2, HDM2, protein protein interactions, small molecule inhibitors, negative regulator, cancer, Angstrom level, p53/MDM2 interaction, derivatives.
Current Pharmaceutical Design
Title:P53 Mdm2 Inhibitors
Volume: 18 Issue: 30
Author(s): Kareem Khoury and Alex Domling
Affiliation:
Keywords: p53, MDM2, HDM2, protein protein interactions, small molecule inhibitors, negative regulator, cancer, Angstrom level, p53/MDM2 interaction, derivatives.
Abstract: The protein-protein interaction (PPI) between p53 and its negative regulator MDM2 comprises one of the most important and intensely studied PPI's involved in preventing the initiation of cancer. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Due to the Angstrom level structural insight there is a reasonable understanding of the structural requirements needed for a molecule to bind to MDM2 and successfully inhibit the p53/MDM2 interaction. The current review summarizes the binding characteristics of the different disclosed small molecules for inhibition of MDM2 with a co-crystal structure. Synthetic access to these compounds as well as their derivatives are described in detail.
Export Options
About this article
Cite this article as:
Khoury Kareem and Domling Alex, P53 Mdm2 Inhibitors, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651580
DOI https://dx.doi.org/10.2174/138161212802651580 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma
Current Cancer Drug Targets Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery Chemosensitization of Prostate Carcinoma Cells with a Receptor-directed Smac Conjugate
Medicinal Chemistry Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
Current Gene Therapy Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Advanced Neuroimaging Techniques in the Management of Glioblastoma Multiforme
Current Radiopharmaceuticals